文献索引：Man, Hon-Wah; Corral, Laura G.; Stirling, David I.; Muller, George W. Bioorganic and Medicinal Chemistry Letters, 2003 , vol. 13, # 20 p. 3415 - 3417
Thalidomide,(1), has made a remarkable comeback from its days of a sedative with teratogenic properties due to its ability to selectively inhibit TNF-α, a key pro-inflammatory cytokine and its clinical benefit in the treatment of cancer. Thalidomide contains one chiral center and is known to be chirally unstable under in vitro and in vivo conditions. It has been hypothesized that different biological properties are associated with each isomer. Thus, ...
